Traceable nanoparticles with mitochondria-targeting pyruvate-Cu induce cuproptosis for enhanced triple negative breast cancer therapy in mouse model

We develop pyruvate with good biocompatibility and mitochondria-targeting ability as a copper ionophore (pyruvate-Cu). To further overcome its drawbacks, traceable nanoparticles are constructed to deliver pyruvate-Cu for triple negative breast cancer (TNBC) treatment. In vitro and in vivo results demonstrate that this work provides an efficient platform for enhanced TNBC therapy.